Arcturus Therapeutics Holdings INC Schedule 13G passive stakes

ARK Investment Management LLC and Catherine D. Wood have jointly filed a Schedule 13G, reporting beneficial ownership of 10.37% of Arcturus Therapeutics Holdings Inc. common stock as of April 30, 2026.

The Vanguard Group has reported zero beneficial ownership in Arcturus Therapeutics Holdings Inc. following an internal realignment.

Balyasny Asset Management and its affiliates have reported a complete divestment of their beneficial ownership in Arcturus Therapeutics Holdings Inc.

ARK Investment Management LLC and Catherine D. Wood filed an Amendment No. 9 on Schedule 13G, disclosing a 9.19% beneficial ownership in Arcturus Therapeutics Holdings Inc.

Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, reporting beneficial ownership of 11.63% of Arcturus Therapeutics Holdings Inc. common stock.

Balyasny Asset Management L.P. and its affiliates have disclosed a beneficial ownership of 8.04% in Arcturus Therapeutics Holdings Inc., holding 2,183,985 shares.

Amova Asset Management Americas, Inc. has reported a 7.2% beneficial ownership stake in Arcturus Therapeutics Holdings Inc., totaling 1,947,835 shares.

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have disclosed a shared beneficial ownership of 7.2% in Arcturus Therapeutics Holdings Inc.

ARK Investment Management LLC and Catherine D. Wood have disclosed a 6.32% beneficial ownership stake in Arcturus Therapeutics Holdings Inc., holding 1,715,040 shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.67% passive ownership stake in Arcturus Therapeutics Holdings Inc. as of June 30, 2025.

Nikko Asset Management Americas, Inc. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 7.1% in Arcturus Therapeutics Holdings Inc. as of March 31, 2025.

Sumitomo Mitsui Trust Group, Inc. and Nikko Asset Management Co., Ltd. have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 7.1% of Arcturus Therapeutics Holdings Inc.'s common stock.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, confirming its beneficial ownership of 7.8% of Arcturus Therapeutics Holdings Inc. common stock as of March 31, 2025.

State Street Corporation has filed a Schedule 13G, reporting a passive beneficial ownership of 4.9% of Arcturus Therapeutics Holdings Inc.'s common stock as of December 31, 2024.